Feedback / Questions
Xifaxan (rifaximin) - Alfa Wassermann, Bausch Health, Norgine
Xifaxan: Initiation of P2/3 trial for Crohn's disease in H1 2020
(Bausch Health)
-
Nov 5, 2019 -
Q3 2019 Results
New P2/3 trial
https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/20191104-3q19-bausch-health-earnings-presentation.pdf
Nov 5, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious